Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease

Bone Marrow Transplantation

Volumn 17, Issue 2, 1996, Pages 185-190

  Miyamoto, T ^a,b   Akashi, K ^a,b   Hayashi, S ^a   Gondo, H ^a,b   Murakawa, M ^a   Tanimoto, K ^a   Harada, M ^b   Niho, Y ^b  

^a HARASANSHIN HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

BMT; GVHD; Soluble IL 2 receptor; TNF

Indexed keywords

INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, INTERLEUKIN-2; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030040845     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of acute graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-vs-Host Disease: Immunology, Pathophysiology and Treatment. Marcel Dekker: New York, 1990, pp 311-335.
2. Gluckman E. Immunosuppressive drugs for the prevention of acute graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-vs-Host Disease: Immunology, Pathophysiology and Treatment. Marcel Dekker: New York, 1990, pp 389-401.
3. Deeg HJ, Storb R. Graft-versus-host disease: pathophysiology and clinical aspects. Ann Rev Med 1984; 35: 11-24.
4. Ferrara JLM, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991; 324: 667-674.
5. Korngold R, Sprent J. T-cell subsets and graft-versus-host disease. Transplantation 1987; 44: 335-339.
6. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
7. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
8. Vogelsana GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood 1994; 84: 2061-2067.
9. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166: 1280-1289.
10. Symington FW, Sullivan PM, Chen AB, Deliganis A. Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplantation 1990; 50: 518-521.
11. McCarthy PL, Abhyankar S, Neben S et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915-1918.
12. Abhyankar S, Gilliand D, Ferar A. Interleukin-1 is a critical effector molecule during cytokine dysregulation and graft-ver-sus-host disease to minor histocompatibility antigens. Transplantation 1994; 56: 1518-1523.
13. Norton J, Sloane JP. ICAM-1 expression of epidermal keratinocytes in cutaneous graft-versus-host disease. Transplantation 1991; 51: 1203-1206.
14. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007-1008.
15. Smith KA. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169-1176.
16. Robb RJ, Munck A, Smith KA. T cell growth factor receptors: quantitation, specificity and biological relevance. J Exp Med 1981; 154: 1455-1474.
17. Robb RJ, Greene W, Rusk C. Low and high affinity cellular receptors for interieukin 2. J Exp Med 1984; 160: 1126-1146.
18. Smith KA. The interieukin 2 receptor. Adv Immunol 1988; 42: 165-179.
19. Rubin LA, Kurman CC, Fritz ME et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172-3177.
20. Tanaka J, Imamura M, Kasai M et al. Cytokine gene expression in the mixed lymphocyte culture in allogeneic bone marrow transplants as a predictive method for transplantation-related complications. Br J Haematol 1994; 87: 415-418.
21. Herve P, Bergerat JP, Bordigoni P et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990; 75: 1017-1023.
22. Anasetti C, Martin PJ, Storb R et al. Treatment of acute graft-versus-host disease with a non-mitogenic anti-CD3 monoclonal antibody. Transplantation 1992; 54: 844-851.
23. Symons JA, Wood NC, Giovine FS, Duff GW. Soluble IL-2 receptor in rheumatoid arthritis: correlation with disease activity. IL-1 and IL-2 inhibition. J Immunol 1988; 141: 2612-2618.
24. Huang YP, Perrin LH, Mieschner PA, Zubler RH. Correlation of T and B cell activities in virro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1988; 141: 827-833.
25. Colvin RB, Preffer FI, Fuller TC et al. A critical analysis of serum and urine interleukin-2 receptor assays in renal allograft recipients. Transplantation 1989; 48: 800-805.
26. Roodman ST, Miller LW, Tsai CC. Role of interleukin 2 receptors in immunologic monitoring following cardiac transplantation. Transplantation 1988; 45: 1050-1056.
27. Perkins JD, Nelson DL, Rakela J et al. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation 1989; 47: 77-81.
28. Shepherd JD, Shore TB, Reece DE et al. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 553-558.
29. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
30. Gondo H, Harada M, Taniguchi S et al. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Bone Marrow Transplant 1993; 12: 437-441.
31. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 895-902.
32. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234-248.
33. Josimovic-Alasevic O, Feldmeier H, Zwingenberger K et al. Interleukin-2 receptor in patients with localized and systemic parasitic disease. Clin Exp Immunol 1988; 72: 249-254.
34. Brown AE, Rieder KT, Webster HK. Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Am Rev Respir Dis 1989; 139: 1036-1038.
35. Siegert W, Josimovic-Alasevic O, Schwerdtfeger R et al. Soluble interleukin 2 receptors in patients after bone marrow transplantation. Bone Marrow Transplant 1990; 6: 97-101.